Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive ...

The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...

The investment firm co-led a $125 million Series A round for Ambros Therapeutics, a Vivek Ramaswamy co-founded company with a ...

Recognizing the urgent need for treatment options and guided by patient insights, Pfizer scientists have discovered a way to ...

The financing follows a strategic shift for Orum, which shelved its original lead program and is now pursuing a potential ...

The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...

Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...

The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

An unusual tussle over the availability of funds for Apple Tree’s startups led the firm to seek protection from creditors ...